罗德凤,祁兢晶,邹振红
LUO Defeng,QI Jingjing,ZOU Zhenhong

• 1:深圳市妇幼保健院临床药学室

摘要(Abstract)：

目的了解哌拉西林/他唑巴坦注射液引起儿童药物不良反应(ADR)的规律和特点,为临床合理用药提供参考。方法对本院2012-01~2014-12收集的58例儿童使用哌拉西林/他唑巴坦注射液的ADR报告进行统计分析。结果 58例儿童使用哌拉西林/他唑巴坦ADR中,男孩ADR发生率(67.24%)明显高于女孩(32.76%);其中新的一般、严重的ADR分别占总数的10.35%和1.72%。临床表现主要为皮疹、过敏反应等皮肤及附件表现,及时经抗休克、抗过敏处理后均可痊愈。结论儿童使用哌拉西林/他唑巴坦注射液时需更加关注临床合理用药,加强ADR的监测,特别是治疗周期较长的应定期监测血常规及肝肾功能,以免发生DRESS综合征等严重不良反应并及时停药。
OBJECTIVE To investigate the rules and characteristics of ADR in children induced by piperacillin / tazobactam,and to provide reference for rational drug application in the clinic. METHODS A total of 58 ADR reports of piperacillin / tazobactam reported in the hospital from January 2012 to December 2014 were analyzed statistically. RESULTS In 58 cases of ADR reports,the proportion of boys(67. 24%) was significantly higher than girls(32. 76%). 10. 35% of the ADR cases were new and 1. 72% of the ADR cases were serious. Main clinical manifestations were lesions of skin and its adnexa. Timely anti-allergic and anti-shock treatment was generally able to quickly relieve symptoms. CONCLUSION Clinicians should pay more attention to piperacillin / tazobactam use in children,strengthen ADR monitoring and dispose to reduce the occurrence of ADR and ensure the safety of medication use. Patients with long treatment cycle should be regularly monitored blood routine examination,hepatic function and renal function,so as to reduce the occurrence of serious ADR such as DRESS syndrome.

关键词(KeyWords)： 儿童;哌拉西林他唑巴坦;不良反应;DRESS综合征
children;piperacillin / tazobactam;adverse reactions;DRESS syndrome

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 罗德凤,祁兢晶,邹振红
LUO Defeng,QI Jingjing,ZOU Zhenhong

参考文献(References)：

• [1]陈新谦,金有豫,汤光.新编药物学(第17版).[M].北京:人民卫生出版社,2011:65.
• [2]郭珩,辛华雯,逄玉涛,等.哌拉西林钠他唑巴坦钠致抽搐[J].药物不良反应杂志,2012,14(5):324.
• [3]杨媛,张威,毛璐,等.哌拉西林钠他唑巴坦钠致白细胞减少的临床特征分析[J].中国医院药学杂志,2014,34(7):550-552.
• [4]鄢由秦.重症支气管扩张患者静脉滴注哌拉西林辕他唑巴坦致血小板急剧下降一例报告[J].临床合理用药,2013,80(6):145.
• [5]Lemieux P,Grégoire JP,Thibeault R,et al.Higher Risk of Neutropenia Associated with Piperacillin-Tazobactam Compared to Ticarcillin-Clavulanate in Children[J].Clin Infect Dis,2015,60(2):203-207.
• [6]Santosa A,Teo BW,Shek LPC.Fixed drug eruption caused by piperacillin-tazobactam[J].Investig Allergol Clin Immunol,2013,23(2):132-133.
• [7]Pratt JA,Stricherz MK,Priya S,et al.Suspected piperacillintazobactam induced nephrotoxicity in the pediatric oncology population[J].Pediatric Blood&Cancer,2014,61(2):366-368.
• [8]Maria-Jose Sanchez-Gonzalez,Jose Barbarroja-Escudero,Dario Antolin Amerigo,et al.DRESS syndrome induced by piperacillin-tazobactam[J].Clinical and Translational Allergy,2014,4(3Suppl):96.
• [9]Calderón O,Fiandor A,Caballero T,et al.DRESS Syndrome Induced by Piperacillin-Tazobactam in Eight Patients[J].Journal of Allergy and Clinical Immunology,2013,131(2Suppl):AB172.
• [10]Reichardt P,Handrick W,Linke A,et al.Leukocytopenia,thrombocytopenia and fever related to piperacillin/tazobactam treatment-a retrospective analysis in 38 children with cystic fibrosi[J].Infection,1999,27(6):355-356.
• [11]姚唯一,潘倩,张安平.药物超敏反应综合征的研究进展[J].中国皮肤性病学杂志,2013,27(8):843-845.
• [12]徐三清,刘艳.哌拉西林/他唑巴坦治疗儿童呼吸道细菌感染的临床疗效与安全性评价[J].中华医院感染学杂志,2013,23(3):660-662.